Abstract | INTRODUCTION: METHODS: RESULTS: 87 patients with breast cancer were classified into different subtypes according to the 12th St. Gallen International Breast Cancer Conference. The response rate to neoadjuvant chemotherapy was significantly different (p = 0.046) between the subgroups. There were significant correlations between pathological complete response (pCR) and ER status (p < 0.0001), HER2 (p = 0.013), molecular subtypes (p = 0.018), T stage (p = 0.024), N stage before chemotherapy (p = 0.04), and type of chemotherapy (p = 0.029). Luminal B type patients had the lowest pCR, followed by luminal A type patients. CONCLUSION: Evaluating molecular subtype's significance in breast cancer prognosis warrants additional studies in our region with extensive data about patient-specific neoadjuvant chemotherapy regimens. Our study was able to reproduce results complementary to those present in the literature in other outcomes.
|
Authors | Ali Atoui, Maroun Bou Zerdan, Ahmad El Mahmoud, Nathalie Chamseddine, Lina Hamad, Hazem I Assi |
Journal | International journal of breast cancer
(Int J Breast Cancer)
Vol. 2022
Pg. 1218128
( 2022)
ISSN: 2090-3170 [Print] Egypt |
PMID | 35190777
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Ali Atoui et al. |